- Home
- FCO vs AGEN Comparison
FCO vs AGEN Comparison
Compare FCO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- AGEN
- Stock Information
- Founded
- FCO 1991
- AGEN 1994
- Country
- FCO United Kingdom
- AGEN United States
- Employees
- FCO N/A
- AGEN N/A
- Industry
- FCO Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FCO Finance
- AGEN Health Care
- Exchange
- FCO Nasdaq
- AGEN Nasdaq
- Market Cap
- FCO 80.3M
- AGEN 96.2M
- IPO Year
- FCO N/A
- AGEN 2000
- Fundamental
- Price
- FCO $5.98
- AGEN $3.32
- Analyst Decision
- FCO
- AGEN Buy
- Analyst Count
- FCO 0
- AGEN 3
- Target Price
- FCO N/A
- AGEN $10.50
- AVG Volume (30 Days)
- FCO 100.1K
- AGEN 357.6K
- Earning Date
- FCO 01-01-0001
- AGEN 03-13-2025
- Dividend Yield
- FCO 14.96%
- AGEN N/A
- EPS Growth
- FCO N/A
- AGEN N/A
- EPS
- FCO 0.43
- AGEN N/A
- Revenue
- FCO N/A
- AGEN $160,427,000.00
- Revenue This Year
- FCO N/A
- AGEN N/A
- Revenue Next Year
- FCO N/A
- AGEN $26.02
- P/E Ratio
- FCO $12.30
- AGEN N/A
- Revenue Growth
- FCO N/A
- AGEN 59.00
- 52 Week Low
- FCO $4.73
- AGEN $2.50
- 52 Week High
- FCO $6.63
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- FCO 46.51
- AGEN 45.96
- Support Level
- FCO $5.92
- AGEN $3.09
- Resistance Level
- FCO $6.12
- AGEN $3.68
- Average True Range (ATR)
- FCO 0.10
- AGEN 0.25
- MACD
- FCO -0.01
- AGEN -0.03
- Stochastic Oscillator
- FCO 17.65
- AGEN 23.00
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).